U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Search Results

Cisplatin Injection
Status: Currently in Shortage
»Date first posted: 02/10/2023
»Therapeutic Categories: Oncology; Pediatric

Expand all

Accord Healthcare Inc. (Revised 02/05/2024)

Company Contact Information:
866-941-7875, option 2

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Injection, 1 mg/1 mL (NDC 16729-288-11) Available, 90 days Coverage Stock Available; Inventory allocating to orders
Injection, 1 mg/1 mL (NDC 16729-288-38) Limited Supply Available, 7 Days Coverage Stock Available; Inventory allocating to orders
Injection, 1 mg/1 mL (NDC 68001-283-27) Unavailable, Timelines not Available at this time Marketed by BluePoint Laboratories. Manufacturing has resumed and intermittent release for Bluepoint Label is planned. Requirements related to complying with good manufacturing practices
Injection, 1 mg/1 mL (NDC 68001-283-32) Unavailable, 30 days Marketed by BluePoint Laboratories. Manufacturing has resumed and intermittent release for Bluepoint Label is planned. Requirements related to complying with good manufacturing practices

Fresenius Kabi USA, LLC (Revised 02/01/2024)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Injection, 1 mg/1 mL (NDC 63323-103-51) Available Check wholesaler for inventory
Injection, 1 mg/1 mL (NDC 63323-103-65) Available Check wholesaler for inventory
Injection, 1 mg/1 mL (NDC 63323-103-64) Available Check wholesaler for inventory

Gland Pharma Limited (Revised 01/15/2024)

Company Contact Information:
Sagent Pharmaceuticals: 866-625-1618

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Cisplatin, Injection, 1 mg/1 mL (NDC 25021-253-50) On backorder. Marketed by Sagent. New launch. Demand increase for the drug
Injection, 1 mg/1 mL (NDC 25021-253-51) Available. On allocation due to high demand Marketed by Sagent. New launch. Demand increase for the drug

Hikma Pharmaceuticals USA, Inc. (Revised 02/22/2024)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Cisplatin Injection, Injection, 1 mg/1 mL (NDC 0143-9504-01) Available Additional lots will be available. Product will be made available as it is released.
Cisplatin Injection, Injection, 1 mg/1 mL (NDC 0143-9505-01) Unavailable Additional lots will be available in the March - April 2024 timeframe. Product will be made available as it is released. Demand increase for the drug

HQ Specialty Pharma (Revised 02/01/2024)

Company Contact Information:
WG Critical Care 888-493-0861

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Injection, 1 mg/1 mL (NDC 44567-511-01) Available Marketed by WG Critical Care
Injection, 1 mg/1 mL (NDC 44567-530-01) Available Marketed by WG Critical Care

Qilu Pharmaceutical Co., Ltd. (Revised 01/15/2024)

Company Contact Information:
Apotex Corp. 800-706-5575

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Injection, 50 mg/50 mL (NDC 60505-6277-0) Product is currently available with one additional batch to be available late February 2024. Qilu Pharmaceutical Co., Ltd., in coordination with the U.S. FDA and Apotex Corp., has initiated temporary importation of CISplatin Injection 50 mg/50 mL (1 mg/mL) vials into the U.S. market to address a drug shortage of CISplatin. Product is available via Apotex Corp.'s authorized distributors. Contact your primary wholesaler/distributor to place orders.

Dear Healthcare Professional Letter: Temporary Importation of CISplatin Injection (50 mg/50 mL) with non-U.S. Labeling to Address Drug Shortage (HYPERLINK)

Demand increase for the drug

Teva Pharmaceuticals USA, Inc. (Revised 02/06/2024)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Cisplatin Injection, Injection, 50 mg/50 mL (NDC 0703-5747-11) Allocating existing supplies
Cisplatin Injection, Injection, 100 mg/100 mL (NDC 0703-5748-11) Allocating existing supplies
Back to Top